News
-
Kinexum And Pennington Biomedical Announce Collaboration For Accelerating Clinical Research Innovation
9/24/2012
Kinexum and Pennington Biomedical Research Center announced plans to establish an integrated approach for emerging companies and early stage therapies to achieve high value regulatory and early phase human clinical trials.
-
ViroPharma And Halozyme Provide Update On Clinical Development Of Subcutaneous Cinryze® (C1 Esterase Inhibitor [Human]) With Recombinant Human Hyaluronidase (rHuPH20)
9/21/2012
ViroPharma Incorporated (Nasdaq: VPHM) and Halozyme Therapeutics, Inc. (Nasdaq: HALO) announced today that the U.S. Food & Drug Administration (FDA) has provided guidance enabling ViroPharma to resume clinical studies of the subcutaneous administration of Cinryze in combination with rHuPH20.
-
MYOS Begins Groundbreaking Clinical Study On Muscle Health; Research Designed To Validate The Strengths Of MYO-T12
9/20/2012
MYOS Corporation (OTCBB: MYOS), a company focused on the discovery, development and commercialization of muscle health and performance therapeutic products, today announced that it has initiated a broad human clinical research study designed to confirm the unique myostatin modulating activities of its first product, MYO-T12™.
-
GNS Healthcare Collaborates With A Leading CRO To Enable More Efficient And Cost-Effective Drug Development
9/19/2012
GNS Healthcare, Inc. (GNS), the leading healthcare data analytics company focused on enabling personalized medicine to improve human health, today announced that it has entered into a collaboration with Covance, one of the world's largest and most comprehensive contract research organizations.
-
Hybrigenics Starts Phase II Clinical Trial Of Inecalcitol In Chronic Lymphocytic Leukemia
9/11/2012
Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext in Paris, with a focus on research and development of new treatments against proliferative diseases, recently announces the start of a phase II clinical trial of oral inecalcitol in patients with chronic lymphocytic leukemia (CLL).
-
Sanofi Pasteur Announces Publication In The Lancet Of World's First Efficacy Results For Its Dengue Vaccine Candidate
9/11/2012
Sanofi Pasteur, the vaccines division of Sanofi, announced recently the online publication in The Lancet of clinical study results showing the ability of its vaccine candidate to protect against dengue fever caused by three dengue virus types. The results of the world’s first efficacy study confirm the excellent safety profile of Sanofi Pasteur’s dengue vaccine candidate.
-
Lilly Stops Phase III Development Of Pomaglumetad Methionil For The Treatment Of Schizophrenia Based On Efficacy Results
8/29/2012
Eli Lilly and Company (NYSE: LLY) announced today the decision to stop ongoing clinical studies investigating pomaglumetad methionil, also known as mGlu2/3, for the treatment of patients suffering from schizophrenia.
-
Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
8/23/2012
Janssen Biologics (Ireland) announced today it has initiated the Phase 3 development program for sirukumab (CNTO 136) as part of a collaboration with GlaxoSmithKline plc (GSK).
-
VolitionRX To Begin Prospective Clinical Trial In Colon Cancer
8/21/2012
VolitionRX Limited, a life sciences company focused on developing blood-based diagnostic tests, announces that its subsidiary Belgian Volition has signed an agreement with the Biobank of CHU UCL Mont-Godinne, an academic hospital in Yvoir, Belgium.
-
AbGenomics International Obtains FDA Agreement On Its Phase 2 Clinical Trial Plans
8/17/2012
Los Altos, CA /PRNewswire-iReach/ - AbGenomics International announced today that it has obtained agreement from U.S. Food and Drug Administration (FDA) for its proposed plans for a phase 2 clinical trial of the novel autoimmune therapeutic candidate, AbGn-168H.